Calidi Biotherapeutics, Inc. Increase Decrease In Operating Lease Liability
Calidi Biotherapeutics, Inc. (CLDI) reported Increase Decrease In Operating Lease Liability of -$667.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$342.00K.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$325.00K.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$312.00K.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$304.00K.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.38M.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.02M.
- Calidi Biotherapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$628.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$667.00K 10-Q · filed 2026-08-13 | -$979.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$325.00K 10-Q · filed 2026-05-14 | -$637.00K derived: sum of 2 quarters · filed 2026-05-14 | -$941.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$616.00K derived: sum of 2 quarters · filed 2026-03-27 | -$1.10M derived: sum of 3 quarters · filed 2026-08-13 | -$1.38M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$789.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.07M 10-Q · filed 2025-11-13 | -$1.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$485.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$764.00K 10-Q · filed 2026-08-13 | -$1.03M derived: sum of 3 quarters · filed 2026-08-13 | -$1.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$279.00K 10-Q · filed 2026-05-14 | -$546.00K derived: sum of 2 quarters · filed 2026-05-14 | -$807.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.06M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$528.00K derived: sum of 2 quarters · filed 2026-03-27 | -$779.00K derived: sum of 3 quarters · filed 2026-03-27 | -$1.02M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$261.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$512.00K derived: sum of 2 quarters · filed 2025-11-13 | -$750.00K 10-Q · filed 2025-11-13 | -$973.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$489.00K 10-Q · filed 2025-08-08 | -$712.00K derived: sum of 3 quarters · filed 2025-08-08 | -$938.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$238.00K 10-Q · filed 2025-05-14 | -$461.00K derived: sum of 2 quarters · filed 2025-05-14 | -$687.00K derived: sum of 3 quarters · filed 2025-05-14 | -$902.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$449.00K derived: sum of 2 quarters · filed 2025-03-31 | -$664.00K derived: sum of 3 quarters · filed 2025-03-31 | -$628.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$441.00K derived: sum of 2 quarters · filed 2024-11-12 | -$405.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$179.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $36.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |